Abcuro completes enrollment of registrational phase 2/3 muscle clinical trial of ulviprubart for the treatment of inclusion body myositis

Newton, mass.--(business wire)--abcuro, inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic t cells, today announced the completion of enrollment of the registrational phase 2/3 muscle clinical trial evaluating ulviprubart (abc008) for the treatment of inclusion body myositis (ibm). “we continue to focus on advancing our product candidate ulviprubart to treat patients with ibm who currently.
IBM Ratings Summary
IBM Quant Ranking